Abstract
Sodium phenylacetate (NaPa) and carboxymethyl benzylamide dextran derivative (CMDBLS4) are able to inhibit growth of breast tumour cells. In this study, we explored whether the combination of NaPa and CMDBLS4 may enhance their respective inhibitory effects on the MCF-7ras cell growth in vitro and in vivo. NaPa inhibited MCF-7ras cell proliferation by reducing the DNA replication concomitantly with a recruitment of cells in G0/G1 phase and by inducing apoptosis in a dose- and time-dependent manner. The addition of CMDBLS4 potentiated the NaPa antiproliferative effect in the manner dependent on the ratio of CMDBLS4 and NaPa concentrations. In nude mice, CMDBLS4 (150 mg kg–1) or NaPa (40 mg kg–1) administrated twice a week, for 7 weeks inhibited MCF-7ras xenograft growth by 40% and 60%, respectively. The treatment by both, CMDBLS4 and NaPa, decreased tumour growth by 83% without any toxicity. To better understand the mechanism of NaPa and CMDBLS4 action we assessed their effect on mitogenic activity of MCF-7ras conditioned medium (CM) on BALBC/3T3 fibroblasts. CMDBLS4 added to the CM, inhibited its mitogenic activity whereas NaPa had an anti-mitogenic effect when CM was prepared from MCF-7ras cells pretreated with NaPa. Thus, the antiproliferative effects of NaPa and CMDBLS4 involve 2 different mechanisms explaining, at least in part, the possible synergism between them. Overall, this study points to the potential use of a combination of dextran derivatives with NaPa to inhibit the breast tumour growth. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adam L, Crepin M, Savin C and Israel L (1995) Sodium phenylacetate induces growth inhibition and Bc12 down regulation and apoptosis in MCF-7ras cells in vitro and in nude mice. Cancer Res 55: 5156–5160
Adam L, Crepin M and Israel L (1997) Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras by sodium phenylacetate and tamoxifene combination. Cancer Res 57: 1023–1029
Albini A, Graf J, Kitten GT, Kleinlan HK, Martin GR, Veillette A and Lippman ME (1986) 17 β estradiol regulates and v-Ha-ras transfection constitutively enhances MCF7 breast cancer cell interactions with basement membrane. Proc Natl Acad Sci USA 83: 8182–8186
Bagheri-Yarmand R, Morere JF, Letouneur D, Jozefonvicz J, Israel L and Crepin M (1992) Inhibitory effect of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res 12: 1641–1646
Bagheri-Yarmand R, Liu JF, Ledoux D, Morere JF and Crépin M (1997) Inhibition of human breast epithelial HBL 100 cell proliferation by a dextran derivative (CMDB7) with FGF2 autocrine loop. Biochem Biophys Res Commun 239: 424–428
Bagheri-Yarmand R, Kourbali Y, Mabilat C, Morere JF, Martin A, Lu LH, Soria C, Jozefonvicz J and Crepin M (1998a) The supression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumor angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7). Br J Cancer 78: 111–118
Bagheri-Yarmand R, Kourbali Y, Morere JF, Jozefonvicz J and Crepin M (1998b) Inhibition of MCF-7ras tumor growth by benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor β1 and platelet-derived growth factor-BB. Cell Growth Differ 9: 497–504
Bagheri-Yarmand R, Kourbali Y, Rath AM, Vassy R, Martin A, Jozefonvicz J, Soria C, He L and Crépin M (1999) Carboxymethyl benzylamide dextran blocks angiogenesis of MDA-MB 435 breast carcinoma xenografted in fad pad and its lung metastases in nude mice. Cancer Res 59: 507–510
Berenbaum KC (1981) Criteria for analysing interaction between biologically active agents. Adv Cancer Res 25: 269–335
Bronzert K, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB and Lippman ME (1987) Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci USA 84: 5763–5767
Chang SM, Kuhn JG, Robin HI, Clifford Schold S, Spence AM, Berger MS, Metha MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C and Prados MD (1999) Phase II study of phenylacetate in patients with recurrent malignant glioma: a north American brain tumor concortium. J Clin Oncol 17: 984–990
Chaubet F, Champion J, Maïga O, Mauray S and Jozefonvicz J (1995) Synthesis and structure-anticoagulant property relationships of functionalized dextrans: CMDBS. Carbohydrate Polymers 28: 145–152
Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelman EP and Lippman ME (1987) Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β estradiol or V-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837–841
Ferrandina G, Melichar B, Loercher A, Verschaegen CF, Kudelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL and Freedman RS (1997) Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 57: 4309–4315
Formigli L, Papucci L, Tani A, Schiavone N, Tempestini A, Orlandini GE, Capaccioli S and Orlandini SZ (2000) Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and nerosis. J Cell Physiol 182: 41–49
Knabbe C, Wakefield L, Flanders K, Kasid A, Derynck R, Lippman ME and Dickson RB (1987) Evidence that TGF β is a hormonally regulated negative growth factor in human breast cancer cell lines. Cell 48: 417–428
Mauzac M and Jozefonvicz J (1984) Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization. Biomaterials 5: 301–304
Mosmann T (1983) Rapid colorimetric assay for cell growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63
Prasanna P, Thilbault A, Liu L and Samid D (1996) Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate and phenylbutyrate. Clin Cancer Res 2: 865–872
Samid D, Shack S and Myers CE (1993) Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non toxic pharmalogical concentration of phenylacetate. J Clin Invest 91: 2288–2295
Samid D, Ram Z, Hudgins WR, Shack S, Liu L, Walbindge S, Oldfild EH and Myers CE (1994) Selective activity of phenylacetate against malignant gliomas: ressemblance to fetal brain damage in phenylketonuria. Cancer Res 54: 891–895
Samid D, Hudgins WR, Shack S, Liu L, Prasanna P and Myers CE (1997) Phenylacetate and phenylbutyrate as novel, nontoxic differenciation inducers. Adv Exp Med Biol 400A: 501–505
Samid D, Wells M, Greene ME, Shen W, Palmer CN and Thibault A (2000) Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res 3: 933–941
Sommers CL, Papageorge A, Wilding G and Gelmann EP (1990) Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of rasH. Cancer Res 50: 67–71
Spandidos DA and Agnantis NJ (1984) Human malignant tumors of the breast as compared to their respective normal tissue have elevated expression of the Harvey ras oncogene. Anticancer Res 4: 269–272
Thibault A, Cooper MR, Figureg WD, Venzan DJ, Sartor OA, Tompkins AC, Weinberg MS, Headlee DJ, Mc Coll Na, Samid D and Myers CE (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690–1694
Thibout D, Di Benedetto M, Kraemer M, Sainte-Catherine O, Derbin C and Crepin M (1998) Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cell lines. Anticancer Res 18: 2657–2662
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Di Benedetto, M., Kourbali, Y., Starzec, A. et al. Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice. Br J Cancer 85, 917–923 (2001). https://doi.org/10.1054/bjoc.2001.1993
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1993
Keywords
This article is cited by
-
Inhibition of epidermoid carcinoma A431 cell growth and angiogenesis in nude mice by early and late treatment with a novel dextran derivative
British Journal of Cancer (2003)
-
Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number
Journal of Cancer Research and Clinical Oncology (2003)
-
Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo
British Journal of Pharmacology (2002)